Barclays Initiates Coverage on Talecris Biotherapeutics (TLCR) with an Equalweight
TLCR Hot Sheet
Rating Summary:1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Barclays initiates coverage on Talecris Biotherapeutics (Nasdaq: TLCR) with an Equalweight rating. Price target $24.
To see more analyst ratings on TLCR Click Here.
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.
To see more analyst ratings on TLCR Click Here.
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- Piper Jaffray Starts Life Technologies (LIFE) at Neutral
- UBS Maintains a 'Neutral' on Patterson Companies (PDCO); Raising 'The Bar' and Estimates
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
